Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cell therapy targets advanced blood cancer

NCT ID NCT05172596

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental cell therapy called PHE885 for adults with multiple myeloma that has returned or stopped responding to multiple standard treatments. Researchers collected immune cells from participants, genetically modified them to target cancer cells, and reinfused them to fight the disease. The main goals were to see how well the treatment worked and how safe it was for patients who had exhausted other options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University School of Medicine-Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Fred Hutch Cancer Research

    Seattle, Washington, 98109, United States

  • Novartis Investigative Site

    Camperdown, New South Wales, 2050, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 01509-900, Brazil

  • Novartis Investigative Site

    Calgary, Alberta, T2N 5G2, Canada

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Athens, 106 76, Greece

  • Novartis Investigative Site

    Thessaloniki, 570 10, Greece

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4678602, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060 8648, Japan

  • Novartis Investigative Site

    Kyoto, Kyoto, 602-8566, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    Riyadh, 11211, Saudi Arabia

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Salamanca, 37007, Spain

  • Novartis Investigative Site

    Glasgow, Scotland, G51 4TF, United Kingdom

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA